NMRA — Neumora Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1885522 ·
Last close
$1.84
Market Cap
$340.92M
52W High
$3.60
52W Low
$1.66
ADV30
1,455,780
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -52,864,000 | -53,458,000 | 153,877,000 | 147,072,000 | 83,197,000 |
| Dec 2025 | 0 | — | -58,480,000 | -59,450,000 | 191,047,000 | 182,530,000 | 87,176,000 |
| Sep 2025 | 0 | — | -57,700,000 | -56,755,000 | 177,833,000 | 129,071,000 | 45,672,000 |
| Jun 2025 | 0 | — | -54,040,000 | -52,731,000 | 223,825,000 | 124,523,000 | 40,946,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-206,440,000
Investing CF
$168,520,000
Financing CF
$77,089,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.45
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,184,149,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-238,398,000
Pretax Income TTM
$-236,798,000
Interest Exp TTM
$2,783,000
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -241,156,000 | -236,928,000 | 191,047,000 | 87,176,000 | — | -206,440,000 |
| Dec 2024 | 0 | -263,464,000 | -243,787,000 | 316,972,000 | 29,908,000 | — | -182,936,000 |
| Dec 2023 | 0 | -252,098,000 | -235,925,000 | 496,195,000 | 27,119,000 | — | -163,278,000 |
| Dec 2022 | 0 | -135,870,000 | -130,904,000 | 426,234,000 | 873,084,000 | — | -114,896,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.89
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FENC | FENNEC PHARMACEUTICALS INC. | $343.55M | $9.89 | — |
| PALI | PALISADE BIO, INC. | $345.42M | $1.99 | — |
| PROK | PROKIDNEY CORP. | $346.79M | $1.69 | — |
| RGNX | REGENXBIO Inc. | $326.21M | $6.31 | — |
| IVVD | Invivyd, Inc. | $324.07M | $1.10 | — |
News headlines (Yahoo Finance, 1h cache)
SoftBank Just Dumped Circle Stock. Don’t Panic and Keep Adding CRCL Here.
2026-05-19 19:49 · Yahoo
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
2026-05-12 20:05 · Yahoo
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-07 11:00 · Yahoo
Neumora Therapeutics (NMRA) Is Among the Best Penny Stocks Set to Explode
2026-04-12 21:45 · Yahoo
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
2026-04-06 11:00 · Yahoo
Neumora Therapeutics, Inc. Common Stock Q4 2025 Earnings Call Summary
2026-03-31 12:30 · Yahoo
Neumora Therapeutics Inc (NMRA) Q4 2025 Earnings Call Highlights: Strong Financial Position ...
2026-03-31 01:01 · Yahoo
Neumora Therapeutics Q4 Earnings Call Highlights
2026-03-30 13:04 · Yahoo
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-03-30 10:53 · Yahoo
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
2026-03-16 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.